Times are still hard for Russian imaging groups despite the rouble stabilising after two years of dramatic decline, says Arkadi Stolpner, the CEO of the largest player. Margins should be around 15% this year, he claims, but his business, the Diagnostic Treatment Centre (DTC), will still expand through 12 nuclear medicine centres over the next three to four years.